Clinical Trials Logo
  1. Home
  2. Colorectal Cancer
  3. NCT02860780
  4. Details
NCT02860780 Clinical Trial

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Colorectal Cancer Clinical Trial

Official title:
A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02860780
Other study ID # 16379
Secondary ID I4D-MC-JTJL2015-
Status Completed
Phase Phase 1
First received
Last updated
Start date August 10, 2016
Est. completion date May 15, 2017

Study information
Verified date November 2017
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.

Recruitment information / eligibility
Status Completed
Enrollment 9
Est. completion date May 15, 2017
Est. primary completion date May 15, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Advanced or metastatic cancer.

- Able to swallow tablets.

- For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer with KRAS and/or BRAF mutations.

- Discontinued all previous treatments for cancer and recovered from the acute effects from the therapy.

Exclusion Criteria:

- Active infection (fungal, viral, or bacterial).

- Active cancer in your brain or spinal cord.

- Acute or chronic leukemia.

- Serious heart condition.

- Disease that requires immunosuppressant therapy.

- Diagnosis of inflammatory bowel disease.

- Major small bowel resection that interferes with your body's ability to absorb the oral medicine.

- Participated in other clinical trials investigating prexasertib or ralimetinib.

- Pregnant or breastfeeding.

- Other pre-existing conditions or medical history which your doctor will explain to you.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• prexasertib
Administered IV
• ralimetinib
Administered orally

Locations
Country Name City State
Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Köln
United States Carolinas Medical Center Charlotte North Carolina
United States Sarah Cannon Research Institute SCRI Nashville Tennessee

Sponsors (1)
Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) of Prexasertib and Ralimetinib Cycle 1 (28 Days)
Secondary Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib Cycle 1 Day 1 through Cycle 3 Day 1 (28 Day Cycles)
Secondary PK: Area Under the Curve (AUC) of Prexasertib Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)
Secondary PK: Cmax of Ralimetinib Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)
Secondary PK: AUC of Ralimetinib Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)
Secondary Best Overall Response (BOR): Percentage of Participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE) Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Estimated up to 32 Weeks)
Secondary Disease Control Rate (DCR): Percentage of Participants who Exhibit SD, CR or PR Baseline through Measured Progressive Disease (Estimated up to 32 Weeks)
Secondary Duration of Response (DOR) Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 32 Weeks)
Secondary Progression Free Survival (PFS) Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 32 Weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A

External Links